STAT3 and neoplasm: Notably, novel biomarkers beyond overexpression of STAT3 pY705 may provide a more comprehensive approach to guiding STAT3-directed treatments and may include upstream ligands such as IL-6 that could be serially monitored with the convenience of a blood test compared to serial tumor biopsies.